Henter indhold
Gitte Marie Henriksen, Institutchef i DEKS (Dansk Institut for Ekstern Kvalitetssikring for Laboratorier i Sundhedssektoren)
SKUP afprøvninger vurderer analysekvalitet og brugervenlighed af patientnært udstyr - derved kan og bør SKUP påvirke hvilke udstyr, der sælges i Skandinavien. Bedre analyseresultater er til gavn for patienten.
SKUP; Skandinavisk afprøvning af laboratorieudstyr til patientnære analyser. SKUP er et samarbejde mellem NOKLUS i Norge, EQUALIS i Sverige og DEKS i Danmark. For mere information se skup.org eller deks.dk.
Uffe Vest Schneider, 1.Reservelæge, Ph.d., DSKM (Dansk Selskab for Klinisk Mikrobiologi)
Mads Nybo, Konst. ledende overlæge Klinisk Diagnostisk Afd., Sydvestjysk Sygehus Esbjerg, og Formand for DSTH (Dansk Selskab for Trombose og Hæmostase)
Ivan Brandslund, Forskningschef, DSKB (Dansk Selskab for Klinisk Biokemi)
Behov for og krav om flere analyser i bedre kvalitet, med større sikkerhed, øjeblikkelige svar og til lavere omkostning til kortlægning af hele patientens situation ud fra et systembiologisk perspektiv i en verden, hvor hver patient har 3-4 forskellige sygdomme, er en god udfordring for vort speciale!
Der skal produceres og integreres data fra proteom, metabolom, genom, mikrobiom og epigenom analyser til en personaliseret profilering mhp precisions diagnostik og risikovurdering samt valg af medicin, behandling og behandlingskontrol.
Kun ved at kombinere storrepertoire producerende enheder i laboratoriet med robotter og kunstig intelligens kan dette opnås.
Men specialet er godt på vej, har ansatte med kompetencerne i fremtidens teknologier, men mangler dog både en mere ideel formålsorienteret funktionel organisation og apparatur integration og ikke mindst financiering af det hastigt stigende analysetal, hvis løftet fra politikerne til befolkningen om verdens bedste sundhedsvæsen skal kunne realiseres.
Karsten Hendriks, Market Development Manager CE - EMEAI, Sciex
Biopharmaceutical process development commonly requires the analysis of hundreds to thousands of samples during clone selection and cell culture optimization. The C100HT Biologics Analyzer uses a 12 channel capillary cassette for parallel electrophoresis separation with LED-induced fluorescence detection to quickly and reproducibly analyze N-glycans released from monoclonal antibodies (mAbs) and similar protein biologics. Its simple sample preparation and fully automated glycan identification facilitate the screening of large numbers of candidates quickly enough for in-process adjustments. Detailed information on each individual sample, including identification of major glycan species, can be reviewed and reported to help you make the right decision for clone selection and cell line optimization.
Sterility is not perfect and has been under scrutiny since its inception, but it remains the best we have as a quality control measure. We will look at the effectiveness and current implementation of sterility testing and what the future holds for this flawed test. How sterility has been harmonised across the Pharmacopoeia’s providing top-level global guidelines that must be followed to ensure specifications are met and remain within the bounds of the regulatory controls. We will look at the debates around sterility from batch sizes, the length of the sterility test and its effect on production and the lack of variation for sterility depending on what organism’s you wish to detected. There will be focus on how any facility can help mitigate the risk of sterility test failure using better processes and continuous environmental monitoring methods. Finally, we look at practical steps you can take to minimising the risk of contamination today.
Simon Foldager Larsen, Nordic Application Manager, AH diagnostics A/S
Changing the course of how diseases are treated and ultimately cured requires a comprehensive understanding of complex cellular phenotypes and their interrelationships in the spatial context of the tissue microenvironment origin from FFPE or froszen sections. Imaging Mass Cytometry™ (IMC™) combined with metal-tagged antibodies empowers simultaneous imaging of 37+ protein markers at subcellular resolution. Gives you unique possibilities to uncover pathology insights, new biomarker correlations and cell interactions. With the Hyperion Imaging system you also gets the possibility to run cells in suspension and analyze 50+ parameters. See how you remove the limitation of Fluorophores by using metal-tagged antibodies and CyTOF technology.
Lauri Paasonen, Application scientist, UPM Biomedicals
In the pursuit of in vitro cell models with improved functionality, materials and methods for three-dimensional (3D) cell culture are a key requirement. GrowDex®, nanofibrillar cellulose (NFC) hydrogel derived from wood, has been shown to provide an effective support matrix aiding the transition from 2D to 3D cellular models.
Anja Mathiesen & Maja Hoi, Senior Account Manager, Molecular Devices
Molecular Devices will present the role of microplate readers and automated imagers for cell culture analysis and visualization. Molecular Devices is helping to advance discovery in cell and protein biology by providing innovative microplate reader and cellular imaging solutions for life science research, pharmaceutical and biotherapeutic development. With over 130,000 placements in laboratories around the world, their instruments have enabled cutting-edge scientific research as described in over 25,000 peer reviewed publications.
Dr. Lutz Ehrhardt, Senior Marketing Manager Centrifugation EMEAI, Beckman Coulter
Beckman Coulter introduced the first AUC sample characterization instrument to help the scientific community power new discoveries. That tradition continues into the 21st century with the new Optima™ AUC system. This latest tool is the most robust technology for providing data used to determine protein stoichiometry in basic protein research and quantification of aggregation levels for academic and biopharma research. This presentation will give you an overview over this fascinating “first principle” technique and with recent application examples of protein and virus characterization gives an impression of the technique´s precision and repeatability, how it supports accessing “Size and Shape-information“ and “Multiwavelength Sedimentation-Analysis.
Eric Jan Cools, Customer Solution Manager, NeuModx
QIAGEN brings in collaboration with NeuMoDx a new revolutionary random access platform that embraces the LEAN philosophy to its fullest. NeuMoDx™ Molecular Systems provide the industry’s first true continuous random-access solution and is scalable to meet the needs of the modern clinical laboratory. The ability to load samples and testing consumables on the fly offers up to 8 hours of operator walkaway capability. Room temperature stable reagents and consumables dramatically reduce waste resulting in unmatched flexibility. Liquid handling and transport is achieved through proven robotic technologies. Our proprietary and unitized microfluidic cartridge features autonomous lanes allowing for simultaneous processing of sample types and varying assays. This unique integration of robotics with advanced microfluidics, reduces operation to three simple steps providing industry leading usability. These capabilities dramatically improve lab productivity and the ability to provide clinicians with critical information in a timely manner.
10.00-13.00
Laboratoriescenen
Danish
English
